‘Take a Photograph’: Big Survival Gain in EGFR-Mutant NSCLC
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced EGFR-mutant NSCLC, but the combination comes with more toxicities.
Medscape Medical News
source https://www.medscape.com/viewarticle/take-photograph-trial-shows-big-survival-gain-advanced-egfr-2025a10007fr?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/take-photograph-trial-shows-big-survival-gain-advanced-egfr-2025a10007fr?src=rss
Comments
Post a Comment